Department of Psychiatry, University of Genova, Genoa, Italy.
Curr Neuropharmacol. 2010 Sep;8(3):287-304. doi: 10.2174/157015910792246227.
To present an updated, comprehensive review on clinical and pre-clinical studies on agomelatine.
A MEDLINE, Psycinfo and Web of Science search (1966-May 2009) was performed using the following keywords: agomelatine, melatonin, S20098, efficacy, safety, adverse effect, pharmacokinetic, pharmacodynamic, major depressive disorder, bipolar disorder, Seasonal Affective Disorder (SAD), Alzheimer, ADHD, Generalized Anxiety Disorder (GAD), Panic Disorder (PD), Obsessive-Compulsive Disorder (OCD), anxiety disorders and mood disorder. STUDY COLLECTION AND DATA EXTRACTION: All articles in English identified by the data sources were evaluated. Randomized, controlled clinical trials involving humans were prioritized in the review. The physiological bases of melatonergic transmission were also examined to deepen the clinical comprehension of agomelatine' melatonergic modulation.
Agomelatine, a melatonergic analogue drug acting as MT(1)/MT(2) agonist and 5-HT(2C) antagonist, has been reported to be an effective antidepressant therapy.
Although a bias in properly assessing the "sleep core" of depression may still exist with current screening instruments, therefore making difficult to compare agomelatine' efficacy to other antidepressant ones, comparative studies showed agomelatine to be an intriguing option for depression and, potentially, for other therapeutic targets as well.
对曲唑酮的临床前和临床研究进行更新、全面的综述。
使用以下关键词在 MEDLINE、Psycinfo 和 Web of Science 上进行搜索（1966 年-2009 年 5 月）：曲唑酮、褪黑素、S20098、疗效、安全性、不良反应、药代动力学、药效学、重性抑郁障碍、双相障碍、季节性情感障碍（SAD）、阿尔茨海默病、注意缺陷多动障碍（ADHD）、广泛性焦虑障碍（GAD）、惊恐障碍（PD）、强迫症（OCD）、焦虑障碍和心境障碍。
评估了通过数据源确定的所有英文文章。在综述中优先考虑涉及人类的随机对照临床试验。还检查了褪黑素能传递的生理基础，以深化对曲唑酮的褪黑素调节的临床理解。
曲唑酮是一种作用于 MT(1)/MT(2)激动剂和 5-HT(2C)拮抗剂的褪黑素类似物药物，已被报道为一种有效的抗抑郁治疗药物。
尽管当前的筛选工具可能仍然存在难以评估“抑郁核心”的偏差，因此难以将曲唑酮的疗效与其他抗抑郁药物进行比较，但比较研究表明，曲唑酮是一种治疗抑郁的有趣选择，并且可能也是其他治疗靶点的选择。
